Taffix, a nasal powder inhaler from Israel's Nasus Pharma, has been found to block viruses from reaching nasal mucosa, and capable of reducing the spread of coronavirus after a "super-spreader" event, the company announced Tuesday.
A user survey for Taffix was conducted in Bnei Brak, a city that has one of Israel's highest morbidity and mortality rates from COVID-19. Members of a local synagogue were offered Taffix and instructed to use it when near a crowded environment during the High Holidays.
Follow Israel Hayom on Facebook and Twitter
The trial participants, as well as a control group, were followed for up to 14 days after the event. Rate of infection in the control group was 10%, compared to those given Taffix, where it stood at 2.4%.
